Organon (OGN) closed at $20.81 in the latest trading session, marking a +0.39% move from the prior day. This change lagged the S&P 500's 0.64% gain on the day. At the same time, the Dow added 1.85%, and the tech-heavy Nasdaq gained 0.2%.The pharmaceutical company's shares have seen an increase of 1.87% over the last month, surpassing the Medical sector's gain of 0.71% and falling behind the S&P 500's gain of 3.82%.Market participants will be closely following the financial results of Organon in its upcoming ...

Organon (OGN) ended the recent trading session at $19.93, demonstrating a -1.04% swing from the preceding day's closing price. This change lagged the S&P 500's 0.07% gain on the day. Elsewhere, the Dow lost 0.13%, while the tech-heavy Nasdaq added 0.14%.The pharmaceutical company's shares have seen a decrease of 2.75% over the last month, not keeping up with the Medical sector's loss of 1.99% and the S&P 500's gain of 4.34%.The investment community will be closely monitoring the performance of Organon in it ...

In the latest market close, Organon (OGN) reached $20.63, with a -0.77% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.04%, and the technology-centric Nasdaq increased by 0.49%.Prior to today's trading, shares of the pharmaceutical company had lost 0.91% over the past month. This has lagged the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time.The upcoming earnings relea ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this pharmaceutical company have returned -0.9% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 0.5% over this period. Now the key question is: Where could the stock be headed in the near term?Altho ...

The latest trading session saw Organon (OGN) ending at $20.45, denoting a +0.49% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow experienced a rise of 0.77%, and the technology-dominated Nasdaq saw a decrease of 0.79%.The pharmaceutical company's shares have seen a decrease of 7.33% over the last month, not keeping up with the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59%.The investment community will be paying close attention t ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this pharmaceutical company have returned -5.1%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 0.9%. The key question now is: What could be the stock's future direction?Although media re ...

From a technical perspective, Organon (OGN) is looking like an interesting pick, as it just reached a key level of support. OGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.The 20-day m ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned +9.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has lost 2.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media repo ...

Organon (OGN) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The upward trend in estimate revisions for this pharmaceutical company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between t ...

Which Healthcare Company Is Best? Joe Raedle/Getty Images News Organon (NYSE:OGN) and Pfizer (PFE) both yield over 5% and are the two highest yielding pharmaceuticals. Bristol-Myers (BMY) is the only other pharmaceutical company that offers a yield above 5% that like Organon and Pfizer, can compete with similarly yielding Treasuries (i.e., those with maturities 12 months or less). Three troubling years of declining double-digit annualized returns have resulted in these well-above average yields. Pfizer ha ...